Common Contracts

COLLABORATION AND OPTION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND ABBVIE IRELAND UNLIMITED COMPANY February 21, 2019

Collaboration and Option Agreement • February 26th, 2019 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Collaboration and Option Agreement
• Filed
  February 26th, 2019
• Company
  Voyager Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

Each Regulatory Milestone Payment set forth in Section 10.2.2(a) is payable only once for each Licensed Compound (e.g., if a [**]). Only one Regulatory Milestone Payment is payable for each Milestone Event for a Licensed Compound, even if multiple Licensed Products that contain or are comprised of such Licensed Compound achieve such Milestone Event. Only one Milestone Payment is payable for each Milestone Event for a Licensed Product, irrespective of the number of Licensed Compounds contained by such Licensed Product. By way of example and not limitation, if a Licensed Product containing or comprised of Licensed Compound x achieves the Milestone Event in Section 10.2.2(a)(ii), then no additional Milestone Payment shall be due if a different Licensed Product containing or comprised of Licensed Compound x achieves such Milestone Event.

Securities and Exchange Commission. Double asterisks denote omissions. COLLABORATION AND OPTION AGREEMENT By and between VOYAGER THERAPEUTICS, INC. AND ABBVIE BIOTECHNOLOGY LTD

Collaboration and Option Agreement • March 14th, 2018 • Voyager Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Collaboration and Option Agreement
• Filed
  March 14th, 2018
• Company
  Voyager Therapeutics, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

This COLLABORATION AND OPTION AGREEMENT (this “Agreement”) is entered into and made effective as of February 16, 2018 (the “Effective Date”), by and between Voyager Therapeutics, Inc., a Delaware corporation, having its principal place of business at 75 Sidney Street, Cambridge, MA 02139 (“Voyager”), and AbbVie Biotechnology Ltd, a corporation organized under the laws of Bermuda having its principal place of business at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda (“AbbVie”). Voyager and AbbVie shall be referred to herein individually as a “Party” and collectively as the “Parties”.